312 Safety and Efficacy of Ruxolitinib Cream for the Treatment of Vitiligo: 104-Week Data From a Phase 2 Study

Abstract

Vitiligo is a chronic autoimmune disease resulting in skin depigmentation. Ruxolitinib cream, a Janus kinase (JAK) 1/JAK2 inhibitor, demonstrated significant repigmentation in a phase 2, dose- ranging, randomized study of adult patients with vitiligo (N=157) when applied to ≤20% total body surface area. Of 80 patients who applied 0.5% ruxolitinib cream once daily (QD), 1.5% QD, or 1.5% twice daily (BID) and completed the 52-week randomized period, 77 continued to apply 1.5% ruxolitinib cream BID in the open-label period for another 52 weeks.